Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSA Vaccines in Advanced Prostate Cancer
NCT00003871Phase 2Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Sep 1999
- Primary completion
- Jun 2002
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of PROSTVAC-F/TRICOM and recombinant vaccinia-prostate-specific antigen vaccine in prostate cancer (PCa) (3 arms), sponsored by Eastern Cooperative Oncology Group. Primary endpoint: Biochemical PSA Progression at 5 years. Started Sep 1999; status: completed.
02
Drugs
PROSTVAC-F/TRICOMrecombinant vaccinia-prostate-specific antigen vaccine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00003871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003871.